Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 689 participants.

Also called NCT01438814

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 689 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01438814
  • EudraCT 2011-002276-16
Other papers using this trial's data
  • Efficacy and safety of linagliptin co-administered with low-dose metformin once daily versus high-dose metformin twice daily in treatment-naïve patients with type 2 diabetes: a double-blind randomized trial Advances in therapy, 2015-03 DOI, PubMed 25805187, PMC4376958 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong SAR China, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01438814. Randomized; double masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2014-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
metformin placebo
Intervention (Drug)
linagliptin placebo
Intervention (Drug)
metformin
Intervention (Drug)
metformin
Intervention (Drug)
linagliptin
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01438814
Content hash
247750097bd4481c2d7ab731cec4ab4d0be3fa08dd69b3ce11b4bb2c8170bbef